Search Results

achieve remission, allogeneic stem cell transplant is a potentially curative option. 3 In a retrospective analyses of 27 patients with anaplastic large cell lymphoma who underwent an allogeneic stem cell transplant, Le Gouill et al 4 found a 55% 5-year

to the recommendation of allogeneic stem cell transplantation (allo-SCT) whenever possible, 6 but its prognostic significance and the optimal treatment of Ph + -AML are not clear. With the current treatment options, the outcome is dismal (with a

or older . Biol Blood Marrow Transplant 2005 ; 11 : 764 – 772 . 64. Tauro S Craddock C Peggs K . Allogeneic stem cell transplantation using a reduced intensity conditioning regimen has the capacity to produce durable remissions and ling

; 2002 . 3. Ng AP Worth L Chen L . Cytomegalovirus DNAemia and disease: incidence, natural history and management in settings other than allogeneic stem cell transplantation . Haematologica 2005 ; 90 : 1672 – 1679 . 4. Thursky KA

similar long-term outcomes for patients treated with each approach. 35 Table 3 Selected Trials of Allogeneic Stem Cell Transplant for Hodgkin Lymphoma Reduced-Intensity and Nonmyeloablative AlloHCT The past 10 to 15 years have seen a

responding to donor lymphocyte infusions following nonmyeloablative stem cell transplantation in multiple myeloma . Blood 2006 ; 107 : 3415 – 3416 . 44. Kroger N Zabelina T Ayuk F . Bortezomib after dose-reduced allogeneic stem cell

nervous system prophylaxis and treatment, and consolidation chemotherapy ( Figure 1 ). Then, depending on risk factors, therapy continues with either maintenance chemotherapy for another 1 to 2 years or allogeneic stem cell transplant in first remission

patients who underwent a transplant in advanced phase. Figure 2 Survival probability after allogeneic stem cell transplant. Tick marks indicate last observation of living patients. From Saussele S, Lauseker M, Gratwohl A, et al. Allogeneic hematopoietic

-cell-depleted, reduced-intensity allogeneic stem cell transplantation with an alemtuzumab-containing conditioning regimen followed by escalated donor lymphocyte infusions . Br J Haematol 2003 ; 123 : 309 – 322 . 11 Attal M Harousseau JL Stoppa AM . High

cytoxan/fludarabine/high-dose rituximab regimen followed by an allogeneic stem cell transplant in patients with relapsed follicular lymphoma to try to reproduce the M. D. Anderson results, because it was a single-center study with potential selection bias